While ACT treatment significantly slowed the growth of control (CTRL) KrasG12D and BrafV600E tumors, loss of Serpinb9 further enhanced the effect of ACT treatment and completely blocked tumor growth in both KrasG12D;Cas9 and BrafV600E;Cas9 mice (Fig. 2A, B). Here, SERPINB9 is linked to neoplasm.